Leslie's 15min chart triggers MACD Death Cross, KDJ Death Cross

Leslie's 15-minute chart has triggered a MACD Death Cross and a KDJ Death Cross as of 10/08/2025 at 14:45. This indicates that the stock price has the potential to continue declining, with momentum shifting towards the downside and potentially leading to further decreases.

Invivyd Inc. (NASDAQ: IVVD), a clinical-stage biopharmaceutical company specializing in monoclonal antibody (mAb) therapies to combat viral threats like COVID-19, has recently seen significant market movements. As of October 8, 2025, at 14:45, Leslie's 15-minute chart has triggered both a MACD Death Cross and a KDJ Death Cross. This technical analysis suggests that the stock price may continue to decline, with momentum shifting towards the downside Invivyd Stock Price, News & Analysis^[1].

The MACD Death Cross occurs when the MACD line crosses below the signal line, indicating a bearish trend. Similarly, the KDJ Death Cross happens when the K line crosses below the J line on the KDJ indicator, signaling a potential reversal in the stock's price movement. These signals can be indicative of a prolonged downtrend, suggesting that investors may want to exercise caution with their investments in Invivyd .

Investors should closely monitor Invivyd's recent developments, such as the FDA clearance of its IND and alignment on the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody to prevent COVID. The company plans to conduct two trials, DECLARATION and LIBERTY, with top-line data anticipated mid-2026. Additionally, Invivyd's appointment of Dr. Paul B. Bolno to its Board of Directors and Kristie Kuhl as Chief Communications Officer highlights its strategic focus on viral infectious diseases and patient advocacy .

Despite these developments, the recent market signals suggest a cautious approach. The company's financial results for Q2 2025 showed a net loss of $14.7 million, although this represents an improvement from the $47.2 million loss in Q2 2024. The market cap of Invivyd stands at approximately $304.5 million, reflecting the current investor sentiment .

In conclusion, while Invivyd continues to make progress in its clinical programs and strategic initiatives, the recent MACD and KDJ Death Crosses indicate a potential downtrend in its stock price. Investors should closely monitor these developments and consider their investment strategies accordingly.